The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

NCT03864185 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions

BIOLOGICAL: Rituximab (genetical recombination)
OTHER: Placebo

Sponsor

Nagoya University

Collaborators

[object Object]
[object Object]